SAN DIEGO, Aug. 2, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2017 financial results and business progress on Wednesday, August 9, 2017, after the close of the U.S. financial markets.
To receive Tocagen's press releases and other investor information, please visit the Investor Relations page of the company's website and register for email alerts.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC).
View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-to-report-second-quarter-2017-financial-results-on-wednesday-august-9-300498658.html
SOURCE Tocagen Inc.
Media Contact: Monica May, Canale Communications, (619) 849-5383, email@example.com; Investor Contact:Elizabeth Broder, The Trout Group, (646) 378-2945, firstname.lastname@example.org